The US Food and Drug Administration (FDA) has cleared Novaliq’s Investigational New Drug (IND) application for NOV05, enabling the initiation of the EYETAC phase II clinical trial ( NCT07285070) in ...
IND clearance marks the first ever cellular rejuvenation therapy using partial epigenetic reprogramming to reach human ...
HOUSTON, Dec. 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development ...
BOSTON, Mass, April 01, 2025 (GLOBE NEWSWIRE) -- Radiance Biopharma, Inc. (“Radiance” or the “Company”), a clinical stage biopharmaceutical company advancing Antibody Drug Conjugates (‘ADCs’), today ...
The FDA cleared the investigational new drug (IND) application for a global phase 3 registrational trial of iSCIB1+, a DNA ...
The application follows guidance provided to IMUNON (IMNN) in Pre-IND meeting with the FDA LAWRENCEVILLE, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage ...
SOMERVILLE, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, today announced that the U.S.
The FDA cleared an investigational new drug application to advance NOV05 in a phase 2 clinical trial in noninfectious ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results